Could the liver hold the key to better cancer treatments? Image: iStock/Md Babul Hosen Could the liver hold the key to better cancer treatments? Penn Medicine researchers have uncovered a liver-based signaling pathway that protects tumors by restraining anticancer immune cells.
Honoring a life scientist’s lifesaving science nocred Honoring a life scientist’s lifesaving science Carl June accepted the 2024 Breakthrough Prize in Life Sciences at a Los Angeles ceremony, making him the sixth recipient from Penn.
Study reveals inequities in access to transformative CAR T cell therapy Image: iStock/PeopleImages Study reveals inequities in access to transformative CAR T cell therapy Penn Medicine researchers have assessed the percentage of patients from minority health populations and reveal inequities in access to transformative CAR T cell therapy.
There’s still no standard test to detect pancreatic cancer early. Scientists are working to change that Penn In the News CNN There’s still no standard test to detect pancreatic cancer early. Scientists are working to change that A 2020 study from the Perelman School of Medicine found that a blood test to screen for certain biomarkers associated with pancreatic cancer was 92% accurate in its ability to detect disease. Accelerating CAR T cell therapy: Lipid nanoparticles speed up manufacturing Image: iStock/Love Employee Accelerating CAR T cell therapy: Lipid nanoparticles speed up manufacturing Penn Engineers have developed a novel method for manufacturing CAR T cells using lipid nanoparticles as delivery vehicles. Mapping pancreatic cancer to improve immunotherapy Gregory L. Beatty is an associate professor of hematology-oncology and member of Penn Medicine’s Abramson Cancer Center. (Image: Courtesy of Penn Medicine News) Mapping pancreatic cancer to improve immunotherapy Gregory L. Beatty, an associate professor of hematology-oncology and member of Penn Medicine’s Abramson Cancer Center, and his team focus on improving immunotherapy for pancreatic cancer. ‘Dual target’ cell therapy appears to shrink brain tumors Image: iStock/Ildar Imashev ‘Dual target’ cell therapy appears to shrink brain tumors Early Penn Medicine trial results show that targeting two tumor-associated proteins in patients with recurrent glioblastoma may be a promising step toward developing cell therapies for solid tumors. A new strategy to attack aggressive brain cancer shrank tumors in two early tests Penn In the News Associated Press A new strategy to attack aggressive brain cancer shrank tumors in two early tests A clinical trial led by Stephen Bagley of the Perelman School of Medicine suggests that targeting two associated proteins with CAR T cell therapy could be a viable strategy for shrinking brain tumors. ‘Switchable’ bispecific antibodies pave way for safer cancer treatment Bispecific T cell engagers are emerging as a powerful class of immunotherapy to treat cancer but are sometimes hindered by unwanted outcomes, such as on-target, off-tumor toxicity; cytokine release syndrome; and neurotoxicity. Now, researchers Penn researchers have developed a novel “switchable” bispecific T cell engager that mitigates these negative effects by co-opting a drug already approved by the FDA. (Image: iStock / CIPhotos) ‘Switchable’ bispecific antibodies pave way for safer cancer treatment Immunotherapy utilizing an FDA-approved drug has enabled Penn researchers to develop a novel switchable bispecific T cell engager that mitigates negative outcomes of immunotherapy. UPenn scientists among those developing vaccines that arm the immune system to fight cancer Penn In the News Philadelphia Inquirer UPenn scientists among those developing vaccines that arm the immune system to fight cancer Penn Medicine researchers like Nobel laureate Drew Weissman are leading efforts to develop a vaccine that prevents cancer, with remarks from Susan Domchek of the Basser Center for BRCA and Robert H. Vonderheide of the Abramson Cancer Center. Load More
Accelerating CAR T cell therapy: Lipid nanoparticles speed up manufacturing Image: iStock/Love Employee Accelerating CAR T cell therapy: Lipid nanoparticles speed up manufacturing Penn Engineers have developed a novel method for manufacturing CAR T cells using lipid nanoparticles as delivery vehicles.
Mapping pancreatic cancer to improve immunotherapy Gregory L. Beatty is an associate professor of hematology-oncology and member of Penn Medicine’s Abramson Cancer Center. (Image: Courtesy of Penn Medicine News) Mapping pancreatic cancer to improve immunotherapy Gregory L. Beatty, an associate professor of hematology-oncology and member of Penn Medicine’s Abramson Cancer Center, and his team focus on improving immunotherapy for pancreatic cancer.
‘Dual target’ cell therapy appears to shrink brain tumors Image: iStock/Ildar Imashev ‘Dual target’ cell therapy appears to shrink brain tumors Early Penn Medicine trial results show that targeting two tumor-associated proteins in patients with recurrent glioblastoma may be a promising step toward developing cell therapies for solid tumors.
A new strategy to attack aggressive brain cancer shrank tumors in two early tests Penn In the News Associated Press A new strategy to attack aggressive brain cancer shrank tumors in two early tests A clinical trial led by Stephen Bagley of the Perelman School of Medicine suggests that targeting two associated proteins with CAR T cell therapy could be a viable strategy for shrinking brain tumors. ‘Switchable’ bispecific antibodies pave way for safer cancer treatment Bispecific T cell engagers are emerging as a powerful class of immunotherapy to treat cancer but are sometimes hindered by unwanted outcomes, such as on-target, off-tumor toxicity; cytokine release syndrome; and neurotoxicity. Now, researchers Penn researchers have developed a novel “switchable” bispecific T cell engager that mitigates these negative effects by co-opting a drug already approved by the FDA. (Image: iStock / CIPhotos) ‘Switchable’ bispecific antibodies pave way for safer cancer treatment Immunotherapy utilizing an FDA-approved drug has enabled Penn researchers to develop a novel switchable bispecific T cell engager that mitigates negative outcomes of immunotherapy. UPenn scientists among those developing vaccines that arm the immune system to fight cancer Penn In the News Philadelphia Inquirer UPenn scientists among those developing vaccines that arm the immune system to fight cancer Penn Medicine researchers like Nobel laureate Drew Weissman are leading efforts to develop a vaccine that prevents cancer, with remarks from Susan Domchek of the Basser Center for BRCA and Robert H. Vonderheide of the Abramson Cancer Center. Load More
‘Switchable’ bispecific antibodies pave way for safer cancer treatment Bispecific T cell engagers are emerging as a powerful class of immunotherapy to treat cancer but are sometimes hindered by unwanted outcomes, such as on-target, off-tumor toxicity; cytokine release syndrome; and neurotoxicity. Now, researchers Penn researchers have developed a novel “switchable” bispecific T cell engager that mitigates these negative effects by co-opting a drug already approved by the FDA. (Image: iStock / CIPhotos) ‘Switchable’ bispecific antibodies pave way for safer cancer treatment Immunotherapy utilizing an FDA-approved drug has enabled Penn researchers to develop a novel switchable bispecific T cell engager that mitigates negative outcomes of immunotherapy.
UPenn scientists among those developing vaccines that arm the immune system to fight cancer Penn In the News Philadelphia Inquirer UPenn scientists among those developing vaccines that arm the immune system to fight cancer Penn Medicine researchers like Nobel laureate Drew Weissman are leading efforts to develop a vaccine that prevents cancer, with remarks from Susan Domchek of the Basser Center for BRCA and Robert H. Vonderheide of the Abramson Cancer Center.